相关实验视频

Updated: Jul 24, 2025

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

前列腺动脉栓塞与良性前列腺增生症 (PARTEM) 患者的医疗治疗:一个随机,多中心,开放标签,第三阶段,优越性试验

Marc Sapoval^1,2, Nicolas Thiounn³, Aurélien Descazeaud⁴

¹Université de Paris Cité, PARCC - INSERM Unité-970, Paris, France.

The Lancet regional health. Europe

|July 7, 2023

概括

与医学治疗相比,前列腺动脉栓塞 (PAE) 在男性良性前列腺增生 (BPH) 中显著改善了尿路症状. 此外,PAE还提供了更大的性症状缓解,并且需要更少的重复治疗.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
最少侵入性手术的方法
医疗器械技术医疗器械技术

背景情况:

良性前列腺增生症 (BPH) 影响着大量男性,导致令人烦的下泌尿道症状 (LUTS).
目前的治疗方法包括药物治疗和微创手术,如前列腺动脉栓塞 (PAE).
将PAE与医疗治疗的疗效和安全性进行比较对于BPH管理至关重要.

研究的目的:

为了比较PAE后症状性BPH患者的症状改善与医学治疗.
评估PAE在减少LUTS和改善生活质量的有效性.
评估两个治疗组之间的性症状变化和再治疗率.

主要方法:

一个随机的,开放的,在10家法国医院进行的优越性试验.
患有BPH (≥50毫升) 和对α阻断剂单疗耐药的LUTS患者被随机分配到PAE或组合疗法 (CT:杜塔斯特/坦素).
主要结局是9个月国际前列腺症状评分 (IPSS) 的变化.

主要成果:

与CT相比,PAE在9个月内显示出IPSS的显著减少 (-10.0对-5.7;p=0.0008).
PAE显示性功能的显著改善 (IIEF-15评分变化:+8.2与-2.8).
9个月后,PAE组中需要重新治疗的患者较少 (5对18).

结论:

与BPH和LUTS抗单一治疗的男性联合医疗相比,PAE提供了优越的泌尿症状缓解.
PAE为性症状提供了显著的好处,并减少了随后侵入性手术的需要.
PAE是一种有效的微创治疗选择,用于症状性BPH.

关键词:

5α-减少酶抑制剂的使用阿尔法阻断剂的使用.良性前列腺增生症良性前列腺增生症费用费用费用费用费用费用费用经济学经济学经济学勃起功能勃起功能勃起功能国际前列腺症状评分国际前列腺症状评分下泌尿道的症状下泌尿道的症状前列腺动脉栓塞的前列腺动脉栓塞

更多相关视频

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...